64 related articles for article (PubMed ID: 33491601)
1. Prevalence of chromosome 8p11.2 translocations and correlation with myeloid and lymphoid neoplasms associated with FGFR1 abnormalities in a consecutive cohort from nine institutions in Japan.
Usuki K; Kameda T; Kawano N; Ito T; Hashimoto Y; Shide K; Kawano H; Sekine M; Toyama T; Iizuka H; Sato S; Takeuchi M; Ishizaki J; Maeda K; Nakai M; Yamashita K; Kubuki Y; Shimoda K
Int J Hematol; 2024 Jun; 119(6):722-727. PubMed ID: 38457113
[TBL] [Abstract][Full Text] [Related]
2. Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.
Malchers F; Nogova L; van Attekum MH; Maas L; Brägelmann J; Bartenhagen C; Girard L; Bosco G; Dahmen I; Michels S; Weeden CE; Scheel AH; Meder L; Golfmann K; Schuldt P; Siemanowski J; Rehker J; Merkelbach-Bruse S; Menon R; Gautschi O; Heuckmann JM; Brambilla E; Asselin-Labat ML; Persigehl T; Minna JD; Walczak H; Ullrich RT; Fischer M; Reinhardt HC; Wolf J; Büttner R; Peifer M; George J; Thomas RK
J Clin Invest; 2023 Nov; 133(21):. PubMed ID: 37606995
[TBL] [Abstract][Full Text] [Related]
3. Adolescent presentation of FGFR1::EBF2 gene fusion mesenchymal tumor.
Jaber O; Sultan I
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23234. PubMed ID: 38593281
[No Abstract] [Full Text] [Related]
4. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.
Rizzo A; Ricci AD; Brandi G
Cancer Treat Res Commun; 2021; 27():100337. PubMed ID: 33611090
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
6. Acute Myeloid Leukemia Evolving from Myeloproliferative Neoplasms: Many Sides of a Challenging Disease.
Mannelli F
J Clin Med; 2021 Jan; 10(3):. PubMed ID: 33498691
[TBL] [Abstract][Full Text] [Related]
7. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
Bekaii-Saab TS; Bridgewater J; Normanno N
Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
[TBL] [Abstract][Full Text] [Related]
8. Current Therapy for Metastatic Urothelial Carcinoma.
Nadal R; Clara JA; Valderrama BP; Bellmunt J
Hematol Oncol Clin North Am; 2021 Jun; 35(3):469-493. PubMed ID: 33958146
[TBL] [Abstract][Full Text] [Related]
9. Emerging agents for the treatment of metastatic urothelial cancer.
Kwon WA; Seo HK
Investig Clin Urol; 2021 May; 62(3):243-255. PubMed ID: 33943047
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors.
Ran K; Zeng J; Wan G; He X; Feng Z; Xiang W; Wei W; Hu X; Wang N; Liu Z; Yu L
Eur J Med Chem; 2021 Aug; 220():113499. PubMed ID: 33940465
[TBL] [Abstract][Full Text] [Related]
11. [New European approvals: Pemigatinib - cholangiocarcinoma with a FGFR2 fusion or rearrangement].
Delaye M; Pernot S
Bull Cancer; 2021 May; 108(5):446-447. PubMed ID: 33931169
[No Abstract] [Full Text] [Related]
12.
Cleary JM; Raghavan S; Wu Q; Li YY; Spurr LF; Gupta HV; Rubinson DA; Fetter IJ; Hornick JL; Nowak JA; Siravegna G; Goyal L; Shi L; Brais LK; Loftus M; Shinagare AB; Abrams TA; Clancy TE; Wang J; Patel AK; Brichory F; Vaslin Chessex A; Sullivan RJ; Keller RB; Denning S; Hill ER; Shapiro GI; Pokorska-Bocci A; Zanna C; Ng K; Schrag D; Jänne PA; Hahn WC; Cherniack AD; Corcoran RB; Meyerson M; Daina A; Zoete V; Bardeesy N; Wolpin BM
Cancer Discov; 2021 Oct; 11(10):2488-2505. PubMed ID: 33926920
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations.
Lee PC; Hendifar A; Osipov A; Cho M; Li D; Gong J
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916849
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2.
Du G; Jiang J; Wu Q; Henning NJ; Donovan KA; Yue H; Che J; Lu W; Fischer ES; Bardeesy N; Zhang T; Gray NS
Angew Chem Int Ed Engl; 2021 Jul; 60(29):15905-15911. PubMed ID: 33915015
[TBL] [Abstract][Full Text] [Related]
15. Case Report: A novel
Zhang Z; Zhu Y; Wang Z; Zeng Z; Wen L; Zhang L; Chen S
Front Oncol; 2023; 13():1276695. PubMed ID: 38023217
[TBL] [Abstract][Full Text] [Related]
16. Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort.
Metzgeroth G; Steiner L; Naumann N; Lübke J; Kreil S; Fabarius A; Haferlach C; Haferlach T; Hofmann WK; Cross NCP; Schwaab J; Reiter A
Leukemia; 2023 Sep; 37(9):1860-1867. PubMed ID: 37454239
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment.
Cowell JK; Hu T
Cancer Drug Resist; 2021; 4(3):607-619. PubMed ID: 34734169
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic FGFR Fusions Produce Centrosome and Cilia Defects by Ectopic Signaling.
Nita A; Abraham SP; Krejci P; Bosakova M
Cells; 2021 Jun; 10(6):. PubMed ID: 34207779
[TBL] [Abstract][Full Text] [Related]
19. Myeloid/lymphoid neoplasm with CEP110-FGFR1 fusion: An analysis of 16 cases show common features and poor prognosis.
Chen M; Wang K; Cai X; Zhang X; Chao H; Chen S; Shen H; Wang Q; Zhang R
Hematology; 2021 Dec; 26(1):153-159. PubMed ID: 33491601
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
